What therapeutic options are available for interstitial cystitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment Options for Interstitial Cystitis/Bladder Pain Syndrome

Treatment for interstitial cystitis should begin with behavioral modifications and manual physical therapy for pelvic floor dysfunction, followed by oral medications (amitriptyline, pentosan polysulfate, or hydroxyzine), with bladder instillations and neuromodulation reserved for refractory cases. 1

Treatment Framework

The 2022 AUA guideline fundamentally restructured IC/BPS management by eliminating the traditional first-through-sixth-line treatment tiers in favor of categorizing therapies into: behavioral/non-pharmacologic, oral medicines, bladder instillations, procedures, and major surgery 1. This shift acknowledges that IC/BPS is heterogeneous and requires individualized, often concurrent multi-modal approaches.

Critical Diagnostic Distinction

Before initiating treatment, perform cystoscopy if Hunner lesions are suspected 1. This is the only consistent cystoscopic finding diagnostic for IC/BPS, and patients with Hunner lesions respond differently to treatment—they should receive early cystoscopic intervention without requiring failure of other therapies first 1.

Behavioral and Non-Pharmacologic Interventions

Start all patients on these approaches:

  • Dietary modification: Identify and eliminate bladder irritants through systematic elimination diet 1
  • Fluid management: Adjust concentration/volume of urine through strategic hydration 1
  • Stress management: Implement techniques to manage stress-induced symptom flares 1
  • Bladder training with urge suppression 1
  • Avoid pelvic floor strengthening exercises (Kegel exercises) 2—these worsen symptoms in IC/BPS patients

Manual Physical Therapy

For patients with pelvic floor tenderness, offer manual physical therapy techniques 2. A high-quality RCT demonstrated that 59% of patients receiving myofascial physical therapy showed moderate-to-marked improvement at 3 months versus 26% with general massage 2. The therapy should focus on:

  • Resolving muscular trigger points in pelvic, abdominal, and hip regions
  • Lengthening muscle contractures
  • Releasing painful scars and connective tissue restrictions

Critical pitfall: Do NOT prescribe pelvic floor strengthening—this exacerbates symptoms 2.

Oral Pharmacologic Therapies

When behavioral measures prove insufficient, consider these oral agents:

Amitriptyline (Grade B Evidence)

  • Superior to placebo for symptom improvement 1
  • Start at 10 mg and titrate gradually to 75-100 mg if tolerated
  • Common adverse effects: sedation, drowsiness, nausea (not life-threatening but affect quality of life) 1

Pentosan Polysulfate (Grade B Evidence)

  • Only FDA-approved oral agent for IC/BPS 1
  • Evidence is contradictory—some trials show benefit, others show no difference from placebo 1
  • Critical warning: Counsel patients on potential risk for macular damage and vision-related injuries before initiating or continuing treatment 1

Hydroxyzine (Grade C Evidence)

  • Clinically significant improvement versus placebo 1
  • Patients with systemic allergies may respond better 1
  • Common adverse effects: short-term sedation, weakness 1

Cimetidine (Grade B Evidence)

  • Clinically significant improvement in symptoms, pain, and nocturia with no reported adverse effects 1

Pain management caveat: Due to the opioid crisis, use chronic opioids judiciously and only after informed shared decision-making with periodic follow-ups. Prioritize non-opioid alternatives 1.

Bladder Instillations

For patients not responding adequately to oral therapies:

  • Dimethyl sulfoxide (DMSO) 3, 4
  • Glycosaminoglycan substitution therapy 3
  • Lidocaine-based anesthetic combinations (often combined with heparin) 3, 4

Interventional Procedures

Cystoscopy with Hydrodistension

  • Both diagnostic and therapeutic 3
  • Particularly important for identifying and treating Hunner lesions 1

Intradetrusor Botulinum Toxin A (Grade C Evidence)

  • Administer if other treatments have failed 2
  • Use 100 units (NOT 200 units—higher dose causes significantly more adverse effects without additional benefit) 2
  • Critical warning: Patient must accept possibility of needing intermittent self-catheterization post-treatment 2
  • The 200-unit dose caused dysuria in nearly half of patients and large post-void residuals in one-third 2

Neuromodulation

  • Sacral neuromodulation for refractory patients 3
  • Posterior tibial nerve stimulation 3, 5

Major Surgery

Reserved exclusively for carefully selected patients with severe, documented bladder-centric disease 1. Options include:

  • Excisional surgery
  • Urinary diversion

These are last-resort options after all conservative and interventional measures have failed 6.

Treatment Algorithm

  1. Confirm diagnosis (symptoms ≥6 weeks, negative cultures) and perform cystoscopy if Hunner lesions suspected 1
  2. Initiate behavioral modifications + manual physical therapy (if pelvic floor tenderness present) 1, 2
  3. Add oral medication: Start with amitriptyline or cimetidine (better safety profile than pentosan polysulfate) 1
  4. If inadequate response: Add bladder instillations 3
  5. If still refractory: Consider botulinum toxin A (100 units) or neuromodulation 2, 3
  6. Last resort: Major surgery only for severe, bladder-centric disease 1, 6

Concurrent multi-modal therapies may be offered rather than strict sequential progression 1. The key is matching treatment intensity to symptom severity while avoiding unnecessary escalation.

References

5
Research

[Alternative treatments for interstitial cystitis].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2009

Related Questions

In a patient with refractory interstitial cystitis/bladder pain syndrome who has failed lifestyle changes, oral analgesics, intravesical therapies, and bladder hydrodistension, what are percutaneous tibial nerve stimulation (PTNS) and transcutaneous tibial nerve stimulation (TTNS) and how are they performed as alternatives before permanent sacral or pudendal nerve‑stimulator implantation?
How do aloe vera capsules benefit patients with interstitial cystitis?
What is the appropriate workup and treatment for a 71-year-old male with interstitial cystitis?
What is the appropriate cimetidine dose for treating interstitial cystitis in an adult who has not responded to conservative measures?
In a patient with interstitial cystitis/bladder pain syndrome refractory to lifestyle measures, oral analgesics, intravesical agents, and bladder hydrodistension, how do sacral nerve stimulation (targeting the S3 root) and pudendal nerve stimulation help improve symptoms?
What is the appropriate initial fluid and insulin management for a patient with a corrected serum sodium of 150 mEq/L, a glucose level of 520 mg/dL, and an anion gap of 12?
Is bupropion an appropriate off‑label treatment for intermittent explosive disorder in an adult patient with no seizure history, no eating disorder, and not on MAO inhibitors?
For atopic dermatitis, should a topical corticosteroid be applied as a cream or an ointment?
How should a patient with a positive Clostridioides difficile toxin A/B assay but a negative enzyme immunoassay be managed?
How should hydrocortisone be administered to a patient?
For a newly admitted patient whose home medication list includes levothyroxine 150 µg daily and who reports taking it consistently with the last dose yesterday, should we restart levothyroxine at the home dose and obtain serum thyroid‑stimulating hormone (TSH) and free thyroxine (free T4) levels given the absence of recent thyroid function tests?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.